- Community-Beiträge
- Aktuellste Threads
Asset Klassen
Kurslisten
Hinweis zu Meine Suchen: Meine Suchen sind aufgrund der vielfachen Bitte aus der Community wieder unter Mein Portfolio zu finden.
Meistgeklickt
Hot News
Heiße Themen (24h)
| Geld/Brief | 6,40 $ / 7,27 $ |
| Spread | +13,59% |
| Schluss Vortag | 6,175 $ |
| Gehandelte Stücke | 75.979 |
| Tagesvolumen Vortag | 242.432,4 $ |
| Tagestief 6,17 $ Tageshoch 6,445 $ | |
| 52W-Tief 5,045 $ 52W-Hoch 9,08 $ | |
| Jahrestief 5,045 $ Jahreshoch 7,67 $ | |
| Umsatz in Mio. | 348,67 $ |
| Operatives Ergebnis (EBIT) in Mio. | -23,38 $ |
| Jahresüberschuss in Mio. | -22,75 $ |
| Umsatz je Aktie | 12,83 $ |
| Gewinn je Aktie | -0,84 $ |
| Gewinnrendite | -6,52% |
| Umsatzrendite | -6,52% |
| Return on Investment | -7,62% |
| Marktkapitalisierung in Mio. | 154,45 $ |
| KGV (Kurs/Gewinn) | -8,00 |
| KBV (Kurs/Buchwert) | 0,95 |
| KUV (Kurs/Umsatz) | 0,52 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +64,37% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 5,65 € | +3,67% | 5,45 € | 12.10.26 | |
| Frankfurt | 5,45 € | +3,81% | 5,25 € | 12.10.26 | |
| Gettex | 5,75 € | +3,60% | 5,55 € | 12.10.26 | |
| L&S RT | 5,775 € | +4,52% | 5,525 € | 12.10.26 | |
| Nasdaq | 6,42 $ | +3,97% | 6,175 $ | 12.10.26 | |
| NYSE | 6,395 $ | +3,06% | 6,205 $ | 12.10.26 | |
| NYSE American | 6,19 $ | 0 % | 6,19 $ | 09.10.26 | |
| Quotrix | 5,55 € | +4,72% | 5,30 € | 12.10.26 | |
| Stuttgart | 5,70 € | +3,64% | 5,50 € | 12.10.26 | |
| Tradegate BSX | 5,30 € | -7,83% | 5,75 € | 02.10.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 09.10.26 | 6,18 | 242 T |
| 08.10.26 | 5,94 | 258 T |
| 07.10.26 | 5,82 | 193 T |
| 06.10.26 | 5,77 | 288 T |
| 05.10.26 | 5,94 | 257 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 5,94 $ | +3,96% |
| 1 Monat | 5,31 $ | +16,29% |
| 6 Monate | 6,33 $ | -2,45% |
| 1 Jahr | 8,16 $ | -24,33% |
| 5 Jahre | 41,76 $ | -85,21% |
| Marktkapitalisierung | 154,45 Mio. $ |
| Streubesitz | 6,62% |
| Währung | USD |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Medizinische Instrumente & Zubehör |
| Aktientyp | Stammaktie |
| +6,59% | BlackRock Inc |
| +4,13% | Acadian Asset Management LLC |
| +4,13% | Armistice Capital, LLC |
| +3,91% | Vanguard Capital Management, LLC |
| +3,53% | AQR Capital Management LLC |
| +3,24% | Ameriprise Financial Inc |
| +3,18% | Dafna Capital Management LLC |
| +2,80% | Arrowstreet Capital Limited Partnership |
| +2,79% | Vanguard MStar Total Stk Mkt Idx Invest |
| +2,44% | iShares Russell 2000 ETF |
| +2,44% | Columbia Small Cap Value Discv A |
| +2,42% | Geode Capital Management, LLC |
| +2,23% | State Street Corp |
| +2,19% | The Goldman Sachs Group Inc |
| +2,04% | Morgan Stanley - Brokerage Accounts |
| +2,02% | Federated Hermes Inc |
| +1,84% | Dimensional Fund Advisors, Inc. |
| +1,81% | JPMorgan Chase & Co |
| +1,80% | Renaissance Technologies Corp |
| +1,56% | CSM Advisors, LLC |
| +1,48% | ExodusPoint Capital Management, LP |
| +1,47% | Jacobs Levy Equity Management, Inc. |
| +1,40% | Federated Hermes MDT Small Cap Core IS |
| +1,24% | Prudential Financial Inc |
| +1,01% | Fidelity Small Cap Index |
| +0,83% | JPMorgan Small Cap Value I |
| +0,82% | iShares Russell 2000 Value ETF |
| +0,59% | Bridgeway Ultra-Small Company |
| +0,57% | BSF Systematic US Eq Abs Ret A2 USD |
| +0,53% | Vanguard Russell 2000 ETF |
| +0,50% | CREF Total Global Stock Account R3 |
| +0,45% | DFA US Small Cap I |
| +0,43% | Columbia VP Small Cap Value Discovery 1 |
| +0,42% | PV BUYBACK USA Classe B USD |
| +0,38% | Federated Hermes MDT Small Cap Core ETF |
| +0,37% | JPMorgan US Small Company L |
| +0,36% | Fidelity Extended Market Index |
| +0,33% | Vanguard Strategic Small-Cap Equity Inv |
| +0,32% | DFA US Micro Cap I |
| +0,29% | iShares Micro-Cap ETF |
| +80,431% | Institutionelle Aktionäre |
| +12,945% | Insider Aktionäre |
| +6,624% | Streubesitz |
Zahlen für Q2/20
Mittlerweile auf einem interessanten Bewertungsniveau angekommen.
https://investor.inogen.com/news-events/press-releases/detail/157/inogen-announces-second-quarter-2020-financial-results
Zahlen für Q1/20
" Inogen is withdrawing its previously announced full year 2020 guidance issued on February 25, 2020 as the Company is unable to estimate the scope, duration, and impact of the COVID-19 PHE for full year 2020. The Company believes it could continue to see a decline in sales in its direct-to-consumer channel until patient mobility and consumer confidence increases. The Company also believes the increase in demand that it experienced for its products in the first quarter in its business-to-business channels due to the COVID-19 PHE may be limited or demand may decline in the future as new COPD patient referrals could decline as physician offices are limiting patient interactions. Given the increased uncertainty around the scope, duration, and impact of the COVID-19 PHE as well as revenue mix between direct-to-consumer and business-to-business channels, Inogen cannot estimate the overall impact to its operations and financial results, which could be material. Due to these uncertainties, the Company is implementing cost savings by delaying certain personnel hires and reducing advertising spend, while also increasing rental setups to improve lead utilization."
https://investor.inogen.com/news-events/press-releases/detail/153/inogen-announces-first-quarter-2020-financial-results
